Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care
Launched by MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH · May 24, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying patients who have suffered from severe brain injuries to understand what factors can predict their recovery over the medium term. Researchers want to identify key elements that can help determine how well these patients might do after treatment. Additionally, they are working on creating a system to continuously assess the quality of care provided in rehabilitation units, ensuring that patients receive the best support possible during their recovery.
To be eligible for this trial, participants need to have a serious brain injury and be admitted to a rehabilitation unit. However, those who were admitted more than 14 weeks after their injury will not be included. If you or your loved one meets these criteria, you can expect to be part of an important study that could improve future care for brain injury patients. The trial is currently looking for participants of all genders who are between the ages of 65 and 74.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with Serious Acquired Brain Injuries
- • admission to rehabilitation units
- Exclusion Criteria:
- • - patients admitted more than 14 weeks after the acute event
About Mario Negri Institute For Pharmacological Research
The Mario Negri Institute for Pharmacological Research is a leading Italian biomedical research organization dedicated to advancing pharmacological science and improving public health. Established in 1963, the Institute focuses on innovative research methodologies, drug development, and clinical trials aimed at understanding and treating various diseases. With a multidisciplinary team of scientists and clinicians, the Institute collaborates with national and international partners to translate research findings into clinical applications, contributing significantly to the fields of pharmacology, epidemiology, and biostatistics. Committed to excellence in research and ethical standards, the Mario Negri Institute plays a vital role in shaping the future of medical science and enhancing therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Correggio, , Italy
Bologna, , Italy
Negrar, , Italy
Ferrara, , Italy
Brescia, , Italy
Bergamo, , Italy
San Giovanni Rotondo, , Italy
Palermo, , Italy
Alessandria, , Italy
Arezzo, , Italy
Baggiovara, , Italy
Cagliari, , Italy
Crotone, , Italy
Foligno, , Italy
Lucca, , Italy
Milano, , Italy
Milano, , Italy
Oristano, , Italy
Parma, , Italy
Rovato, , Italy
Telese Terme, , Italy
Trento, , Italy
Vicenza, , Italy
Firenze, , Italy
Imola, , Italy
Piacenza, , Italy
Sant'angelo Dei Lombardi, , Italy
Patients applied
Trial Officials
Guido Bertolini
Study Chair
Istituto Di Ricerche Farmacologiche Mario Negri
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials